Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
Background and objectives: Once-daily, fixed-combination calcipotriol 50 µg/g (Cal) plus betamethasone dipropionate 0.5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/...
| Authors: | , , , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2022 |
| Country: | España |
| Institution: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repository: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p15898 |
| Online Access: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15898 https://ddd.uab.cat/record/284450 |
| Access Level: | Open access |
| Keyword: | betamethasone dipropionate calcipotriol betamethasone betamethasone-17,21-dipropionate dermatological agent emollient agent prostaglandin A adult Article assessment of humans combination drug therapy comparative effectiveness controlled study cream drug dosage form comparison drug efficacy drug formulation female foam human major clinical study male middle aged outcome assessment patient coding Physician Global Assessment Psoriasis Area and Severity Index psoriasis vulgaris aerosol drug combination psoriasis treatment outcome Aerosols Betamethasone Dermatologic Agents Drug Combinations Emollients Humans Prostaglandins A Psoriasis Treatment Outcome |
| Summary: | Background and objectives: Once-daily, fixed-combination calcipotriol 50 µg/g (Cal) plus betamethasone dipropionate 0.5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream. Methods: Anchored and unanchored MAIC analyses were conducted using individual patient data (IPD) from five Cal/BD foam trials and two trials of Cal/BD cream. Outcomes of interest were the proportion of patients with Physician's Global Assessment (PGA) success and the mean reduction in modified Psoriasis Area and Severity Index (mPASI). Results: In the anchored MAIC, patients were more likely to achieve PGA success after 4 weeks of Cal/BD foam than after 8 weeks of Cal/BD cream and had larger mean improvements in mPASI (p <.01 in EU mPASI analysis). In unanchored analyses, 4 weeks of Cal/BD foam treatment was statistically significantly more efficacious in inducing PGA success than 8 weeks of Cal/BD cream (p <.01 in five of six comparisons). Mean reductions in mPASI were consistently statistically significantly greater with Cal/BD foam than with Cal/BD cream. Conclusions: Use of Cal/BD foam consistently shows significantly greater improvements in PGA and mPASI outcomes, compared with Cal/BD cream. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. |
|---|